New Achievement
-
- Highly pathogenic avian influenza virus (HPAIV)
Jun 04, 2026Evaluation of the Efficacy of Low-Concentration Gaseous Chlorine Dioxide in Inactivating Airborne H5 High Pathogenicity Avian Influenza Virus in Vivo Model -
- COVID-19
Jun 01, 2026Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. FDA Approval of Xocova® for COVID-19 Prevention -
- probiotics
Oct 31, 2025Enhancement of Vaccine-Induced T-Cell Responses by Probiotics in Calves





